Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

The firm has dosed the first patient in a China-based study testing JSKN016 in participants who have failed two or more prior treatments.

Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.R&D Expenses was approximately RMB1319.68 ...

A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according ...

GSK plc has received Orphan Drug Designation in Japan for its investigational antibody-drug conjugate risvutatug rezetecan (Ris-Rez) for the treatment of small-cell lung cancer, supported by early ...